A disproportionality analysis of FDA adverse event reporting system events for misoprostol
Abstract Misoprostol was originally used to treat gastric ulcers, and has been widely used in abortion, cervical maturation, induced labour and postpartum hemorrhage. But there are still many undetected adverse events (AEs). The purpose of this study was to provide a comprehensive overview of the sa...
Saved in:
Main Authors: | Li Yang, Wenting Xu |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2025-01-01
|
Series: | Scientific Reports |
Subjects: | |
Online Access: | https://doi.org/10.1038/s41598-025-86422-z |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Disproportionality analysis of upadacitinib-related adverse events in inflammatory bowel disease using the FDA adverse event reporting system
by: Shiyi Wang, et al.
Published: (2025-02-01) -
A real-world Pharmacovigilance study of brodalumab based on the FDA adverse event reporting system
by: Ke He, et al.
Published: (2025-01-01) -
Post-Marketing Pharmacovigilance of Canakinumab from the FDA Adverse Event Reporting System (FAERS)
by: Weidong Zhang, et al.
Published: (2025-01-01) -
Safety assessment of rosuvastatin-fenofibrate combination in the treatment of hyperlipidemia based on FDA’s adverse event reporting system database
by: Qun Li, et al.
Published: (2025-02-01) -
The real-world safety of Ofatumumab: a pharmacovigilance analysis based on the FDA adverse event reporting system
by: Yue Zhou, et al.
Published: (2025-01-01)